|
|
|
|
|
|
|
|
|
|
Editorial
Breaking Down the Evidence for Bevacizumab in Ovarian Cancer
The Oncologist first published on January 19, 2015; doi:10.1634/theoncologist.2014-0302
Bevacizumab has been
FDA-approved for use in combination with single-agent chemotherapy for
platinum-resistant ovarian cancer; however, its optimal role remains
unclear. In this editorial, the timing, efficacy, safety, and rationale
for use of bevacizumab in ovarian cancer are discussed.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.